Vaccine Trials

“A phase I/II clinical trial to evaluate the safety and immunogenicity of a multiclade HIV-1 DNA plasmid vaccine boosted by a multiclade HIV-1 recombinant adenovirus-5 vector vaccine in HIV uninfected adult volunteers in East Africa”

Purpose

The objectives of the study were to evaluate the safety and immunogenicity of a multiclade A, B and C HIV DNA prime (VRC-HIVDNA016-00-VP) boosted with a multiclade A, B and C recombinant Adenovirus type 5 vector (VRC-HIVADV014-00-VP). The vaccine was provided by the NIH Vaccine Research Center (VRC) consisting of a multiclade A, B and C HIV DNA prime (VRC-HIVDNA016-00-VP) boosted with a multiclade A, B and C recombinant Adenovirus type 5 vector (VRC-HIVADV014-00-VP).

Team: Leonard Maboko (Principal Investigator), Mirjam Schunk, Arne Kroidl (Clinical Research Coordinator)

You can reach us at:

NIMR - Mbeya Medical Research Center
P.O Box 2410
Hospital Hill rd, Mbeya Tanzania

Tel +255 25 250 3364
Fax +255 25 250 3134

Working hours:
Mon - Fri
08:00 - 17:00 EAT (GMT + 3)

Or send us an email at This email address is being protected from spambots. You need JavaScript enabled to view it.

Our Twitter Feed

NIMRMbeya Leadership skills development workshop organized by Tanzania Global Learning Agency to @NIMRMbeya leadership team,… https://t.co/CHUsREcpwi
NIMRMbeya RT @TBtrials_StAnd: “We MUST run faster than the diseases through prevention & management factoring multidisciplinary approaches collaborat…
NIMRMbeya Deputy Minister MoHCDGEC Dr. Faustine Ndugulile (sitted at the center) in a group photo with members of the Execu… https://t.co/g6GVYT9mu3
NIMRMbeya Deputy Minister MoHCDGEC Dr. Faustine Ndugulile giving a commencement speech for the annual PanACEA Consortium mee… https://t.co/p3XGG56KBd
© 2017 NIMR - Mbeya Medical Research Center